The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, NewAmsterdam Pharma Company NV (NASDAQ: NAMS) closed at $33.68 down -1.58% from its previous closing price of $34.22. In other words, the price has decreased by -$1.58 from its previous closing price. On the day, 0.84 million shares were traded. NAMS stock price reached its highest trading level at $34.8 during the session, while it also had its lowest trading level at $33.32.
Ratios:
For a deeper understanding of NewAmsterdam Pharma Company NV’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.57 and its Current Ratio is at 12.57. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On August 25, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $45.
On July 17, 2025, Goldman started tracking the stock assigning a Neutral rating and target price of $27.Goldman initiated its Neutral rating on July 17, 2025, with a $27 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 02 ’25 when Bain Capital Life Sciences Fun bought 267,429 shares for $38.33 per share.
BCLS II Investco, LP bought 4,500,000 shares of NAMS for $172,485,000 on Dec 02 ’25. On Dec 02 ’25, another insider, BCIP Life Sciences Associates, who serves as the Former Affiliate of the company, bought 32,571 shares for $38.33 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAMS now has a Market Capitalization of 3819002112 and an Enterprise Value of 3116322304. For the stock, the TTM Price-to-Sale (P/S) ratio is 108.37 while its Price-to-Book (P/B) ratio in mrq is 5.24. Its current Enterprise Value per Revenue stands at 88.424 whereas that against EBITDA is -15.373.
Stock Price History:
The Beta on a monthly basis for NAMS is 0.09, which has changed by 0.34406912 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, NAMS has reached a high of $42.00, while it has fallen to a 52-week low of $14.06. The 50-Day Moving Average of the stock is -9.29%, while the 200-Day Moving Average is calculated to be 31.64%.
Shares Statistics:
For the past three months, NAMS has traded an average of 1.12M shares per day and 1302690 over the past ten days. A total of 113.17M shares are outstanding, with a floating share count of 80.55M. Insiders hold about 28.96% of the company’s shares, while institutions hold 67.15% stake in the company. Shares short for NAMS as of 1764288000 were 6677161 with a Short Ratio of 5.97, compared to 1761868800 on 6424987. Therefore, it implies a Short% of Shares Outstanding of 6677161 and a Short% of Float of 7.0199996.
Earnings Estimates
The stock of NewAmsterdam Pharma Company NV (NAMS) is currently being evaluated by 13.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.31 and low estimates of -$0.5.
Analysts are recommending an EPS of between -$1.01 and -$1.58 for the fiscal current year, implying an average EPS of -$1.34. EPS for the following year is -$1.5, with 11.0 analysts recommending between -$1.15 and -$2.08.
Revenue Estimates
A total of 14 analysts have provided revenue estimates for NAMS’s current fiscal year. The highest revenue estimate was $45.34M, while the lowest revenue estimate was $19.13M, resulting in an average revenue estimate of $23.44M. In the same quarter a year ago, actual revenue was $43.39M
